Related Experiment Videos
[Clinical experiences with depot neuroleptics]
Psychiatrie, Neurologie Und Medizinische Psychologie. Beihefte
|January 1, 1975
Summary
Long-acting injectable antipsychotics like Fluphenazine decanoate and Flupenthixol decanoate demonstrate effectiveness in treating schizophrenia and related psychoses. These depot neuroleptics offer a valuable addition to therapy, achieving sustained remissions for over three years in some patients.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Neuroscience
Context:
- Evaluation of long-acting injectable antipsychotics in patients with acute/sub-acute schizophrenia, paraphrenia, and paranoic atypical psychoses.
- Assessment of therapeutic effectiveness of Fluphenazine decanoate, Fluphenazine enanthate, and Flupenthixol decanoate.
- Study involved 27 patients with schizophrenia and 15 with other psychotic disorders.
Purpose:
- To assess the therapeutic effectiveness of specific depot neuroleptics in treating various psychotic disorders.
- To determine if significant differences exist between Fluphenazine decanoate, Fluphenazine enanthate, and Flupenthixol decanoate.
- To evaluate the long-term efficacy and impact of depot antipsychotic therapy.
Summary:
- No significant distinctions were observed between the tested depot neuroleptic combinations.
- Long-term treatment with depot neuroleptics is a suitable and valuable addition to antipsychotic therapy.
- Uninterrupted remissions exceeding three years were achieved in several patients.
Impact:
- Highlights the clinical utility of long-acting injectable antipsychotics for sustained symptom control.
- Suggests depot neuroleptics can improve long-term outcomes and remission rates in psychotic disorders.
- Provides evidence for the effectiveness of these agents in managing chronic psychiatric conditions.